{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T23:25:12Z","timestamp":1784676312002,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40265-018-0935-1","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T07:07:57Z","timestamp":1528787277000},"page":"941-950","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5104-1158","authenticated-orcid":false,"given":"Katherine A.","family":"Lyseng-Williamson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,12]]},"reference":[{"key":"935_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/TCRM.S126143","volume":"14","author":"DL Chan","year":"2018","unstructured":"Chan DL, Singh S. Developments in the treatment of carcinoid syndrome: impact of telotristat. Ther Clin Risk Manage. 2018;14:323\u20139.","journal-title":"Ther Clin Risk Manage"},{"issue":"3","key":"935_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-017-0461-5","volume":"18","author":"M Cives","year":"2017","unstructured":"Cives M, Strosberg J. Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract. Curr Treat Options Oncol. 2017;18(3):1\u201314.","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"935_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/cncr.29099","volume":"121","author":"J Hallet","year":"2015","unstructured":"Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemilogy, metastatic presentation, and outcome. Cancer. 2015;121(4):589\u201397.","journal-title":"Cancer"},{"issue":"2","key":"935_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1177\/1758834016675803","volume":"9","author":"RP Riechelmann","year":"2017","unstructured":"Riechelmann RP, Pereira AA, Rego JFM, et al. Refractory carcinoid syndrome: a review of treatment options. Ther Adv Med Oncol. 2017;9(2):127\u201337.","journal-title":"Ther Adv Med Oncol"},{"key":"935_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/9856140","author":"KI Alexandraki","year":"2017","unstructured":"Alexandraki KI, Karapanagioti A, Karoumpalis I, et al. Advances and current concepts in the medical management of gastroenteropancreatic neuroendocrine neoplasms. Biomed Res Int. 2017. https:\/\/doi.org\/10.1155\/2017\/9856140 .","journal-title":"Biomed Res Int"},{"issue":"11","key":"935_CR6","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/j.clinthera.2017.09.013","volume":"39","author":"L Anthony","year":"2017","unstructured":"Anthony L, Ervin C, Lapuerta P, et al. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017;39(11):2158\u201368.","journal-title":"Clin Ther"},{"issue":"1","key":"935_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1124\/jpet.107.132670","volume":"325","author":"Q Liu","year":"2008","unstructured":"Liu Q, Yang Q, Sun W, et al. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J Pharmacol Exp Ther. 2008;325(1):47\u201355.","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"935_CR8","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.tips.2018.03.004","volume":"39","author":"S Matthes","year":"2018","unstructured":"Matthes S, Bader M. Peripheral serotonin synthesis as a new drug target. Trends Pharmacol Sci. 2018;39(6):560\u201372.","journal-title":"Trends Pharmacol Sci"},{"key":"935_CR9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/MPA.0b013e3182328045","volume":"41","author":"J Beaumont","year":"2012","unstructured":"Beaumont J, Cella D, Phan A, et al. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41:461\u20136.","journal-title":"Pancreas."},{"issue":"8 Suppl","key":"935_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1200\/JCO.2017.35.8_suppl.151","volume":"35","author":"G Goldstein","year":"2017","unstructured":"Goldstein G, Evans K, Shah A, et al. Carcinoid Syndrome Impact Survey: evaluation of the burden of illness and the gap between patient and oncologist perceptions [abstract no. 151 plus poster]. J Clin Oncol. 2017;35(8 Suppl):151.","journal-title":"J Clin Oncol"},{"issue":"6","key":"935_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","volume":"46","author":"JR Strosberg","year":"2017","unstructured":"Strosberg JR, Halfdanarson TR, Bellizzi AM, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas. 2017;46(6):707\u201314.","journal-title":"Pancreas"},{"key":"935_CR12","unstructured":"Xermelo: summary of product characteristics. London: European Medicines Agency. 2018."},{"key":"935_CR13","unstructured":"Xermelo (telotristat ethyl) tablets, for oral use: US prescribing information. The Woodlands: Lexicon Pharmaceuticals, Inc. 2017."},{"issue":"Suppl 1","key":"935_CR14","first-page":"S21","volume":"61","author":"T Oravecz","year":"2012","unstructured":"Oravecz T, Jhaver K, Yang QM, et al. LX1606, a peripheral inhibitor of serotonin synthesis, alleviates development of inflammatory bowel disease in a preclinical model [abstract no. A128]. Inflamm Res. 2012;61(Suppl 1):S21.","journal-title":"Inflamm Res"},{"issue":"6","key":"935_CR15","doi-asserted-by":"publisher","first-page":"G455","DOI":"10.1152\/ajpgi.00299.2014","volume":"309","author":"JJ Kim","year":"2015","unstructured":"Kim JJ, Wang H, Terc JD, et al. Blocking peripheral serotonin synthesis by telotristat etiprate (LX1032\/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2015;309(6):G455\u201365.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"6","key":"935_CR16","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1136\/gutjnl-2013-304901","volume":"63","author":"KG Margolis","year":"2014","unstructured":"Margolis KG, Stevanovic K, Li Z, et al. Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut. 2014;63(6):928\u201337.","journal-title":"Gut"},{"issue":"5 Suppl 1","key":"935_CR17","first-page":"56","volume":"136","author":"SC Pappas","year":"2009","unstructured":"Pappas SC, Brown P, Turnage A, et al. LX1032: a potential new therapy for chronic diarrhea in carcinoid syndrome (CS) [abstract no. 352]. Gastroenterology. 2009;136(5 Suppl 1):56.","journal-title":"Gastroenterology"},{"issue":"5","key":"935_CR18","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1530\/ERC-14-0173","volume":"21","author":"MH Kulke","year":"2014","unstructured":"Kulke MH, O\u2019Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014;21(5):705\u201314.","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"935_CR19","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1210\/jc.2014-2247","volume":"100","author":"M Pavel","year":"2015","unstructured":"Pavel M, H\u00f6rsch D, Caplin M, et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab. 2015;100(4):1511\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"935_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","volume":"35","author":"MH Kulke","year":"2017","unstructured":"Kulke MH, H\u00f6rsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35(1):14\u201323.","journal-title":"J Clin Oncol"},{"issue":"3","key":"935_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1530\/ERC-17-0455","volume":"25","author":"M Pavel","year":"2018","unstructured":"Pavel M, Gross D, Benavant M, et al. Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial. Endocr Relat Cancer. 2018;25(3):309\u201322.","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"935_CR22","first-page":"341","volume":"47","author":"D H\u00f6rsch","year":"2018","unstructured":"H\u00f6rsch D, Kulke MH, Caplin M, et al. Efficacy and safety of telotristat ethyl in patients with carcinoid syndrome inadequately controlled by somatostatin analogs: analysis of the completed TELESTAR extension period [abstract]. Pancreas. 2018;47(3):341\u20132.","journal-title":"Pancreas"},{"key":"935_CR23","unstructured":"US National Institutes of Health. Study to compare a dose of telotristat etiprate in subjects with renal impairment with matched subjects with normal renal function [NCT03442725]. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03442725?term=NCT03442725&rank=1 . Accessed 6 Jun 2018."},{"key":"935_CR24","unstructured":"US National Institutes of Health. Study to evaluate the pharmacokinetics of telotristat ethyl in subjects with severe hepatic impairment [NCT03423446]. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03423446?term=NCT03423446&rank=1 . Accessed 6 Jun 2018."},{"key":"935_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.04.006","author":"MO Weickert","year":"2018","unstructured":"Weickert MO, Kaltsas G, H\u00f6rsch D, et al. Changes in weight associated with telotristat ethyl in the treatment of carcinoid syndrome. Clin Ther. 2018. https:\/\/doi.org\/10.1016\/j.clinthera.2018.04.006 (Epub 2018. pii: S0149-2918(18)30148-6).","journal-title":"Clin Ther"},{"issue":"Suppl 1","key":"935_CR26","first-page":"232","volume":"105","author":"D Cella","year":"2017","unstructured":"Cella D, Beaumont J, Hudgens S, et al. Relationship between symptoms and HRQoL benefits in patients with carcinoid syndrome (CS): a post-hoc analysis of telotristat ethyl (TE) TELESTAR trial [abstract no. M3 plus poster]. Neuroendocrinology. 2017;105(Suppl 1):232.","journal-title":"Neuroendocrinology"},{"issue":"Suppl 1","key":"935_CR27","first-page":"212","volume":"105","author":"LB Anthony","year":"2017","unstructured":"Anthony LB, Kulke MH, H\u00f6rsch D, et al. Impact of concomitant medication on efficacy of telotristat ethyl: a post hoc subgroup analysis of the phase 3 TELESTAR study in carcinoid syndrome [abstract no. L2 plus poster]. Neuroendocrinology. 2017;105(Suppl 1):212.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"935_CR28","first-page":"337","volume":"47","author":"JS Dillon","year":"2018","unstructured":"Dillon JS, Kulke M, Pavel M, et al. Time to sustained improvement in bowel movement frequency with telotristat ethyl: analysis of the phase 3 TELESTAR study [abstract]. Pancreas. 2018;47(3):337\u20138.","journal-title":"Pancreas"},{"issue":"Suppl 1","key":"935_CR29","first-page":"237","volume":"105","author":"M Pavel","year":"2017","unstructured":"Pavel M, H\u00f6rsch D, Hoffmanns P, et al. Correlation of plasma (p) and urine (u) 5-HIAA levels in patients (pts) with carcinoid syndrome: post-hoc analyses from the TELESTAR study [abstract no. M8 plus poster]. Neuroendocrinology. 2017;105(Suppl 1):237.","journal-title":"Neuroendocrinology"},{"issue":"Suppl 6","key":"935_CR30","first-page":"vi136","volume":"27","author":"M Kulke","year":"2016","unstructured":"Kulke M, H\u00f6rsch D, Caplin M, et al. Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome [abstract no. 422PD]. Ann Oncol. 2016;27(Suppl 6):vi136\u201348.","journal-title":"Ann Oncol."},{"issue":"Suppl 5","key":"935_CR31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdx368.014","volume":"28","author":"P Lapuerta","year":"2017","unstructured":"Lapuerta P, Kulke MH, Caplin M, et al. Long-term survival of patients with carcinoid syndrome in clinical trials of telotristat ethyl [abstract no. 442P plus poster]. Ann Oncol. 2017;28(Suppl 5):147\u20138.","journal-title":"Ann Oncol"},{"key":"935_CR32","unstructured":"Lapuerta P, Kulke M, Pavel M et al. Integrated safety analysis of telotristat ethyl in patients with carcinoid heart disease [abstract no. L7 plus poster]. In: 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease [abstract booklet]. Berlin: European Neuroendocrine Tumor Society. 2017. p. 237."},{"issue":"1","key":"935_CR33","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1097\/MPA.0000000000000971","volume":"47","author":"PM Kasi","year":"2018","unstructured":"Kasi PM. Telotristat ethyl for patients with carcinoid syndrome associated with chest pain and hypertension [letter]. Pancreas. 2018;47(1):e2. https:\/\/doi.org\/10.1097\/MPA.0000000000000971 .","journal-title":"Pancreas"},{"key":"935_CR34","unstructured":"National Comprehensive Cancer Network\u00ae. Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Neuroendocrine and adrenal tumors (version 2.2018). Fort Washington: National Comprehensive Cancer Network\u00ae, Inc. 2018."},{"issue":"2","key":"935_CR35","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/13696998.2017.1387120","volume":"21","author":"VN Joish","year":"2017","unstructured":"Joish VN, Frech F, Lapuerta P. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. J Med Econ. 2017;21(2):182\u20138.","journal-title":"J Med Econ"},{"issue":"12","key":"935_CR36","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.clinthera.2017.10.019","volume":"39","author":"VN Joish","year":"2017","unstructured":"Joish VN, Frech F, Lapuerta P. Budgetary impact of telotristat ethyl, a novel treatment for carcinoid syndrome diarrhea patients: a US health plan perspective. Clin Ther. 2017;39(12):2338\u201344.","journal-title":"Clin Ther"},{"issue":"9","key":"935_CR37","doi-asserted-by":"publisher","first-page":"A548","DOI":"10.1016\/j.jval.2017.08.852","volume":"20","author":"K Fust","year":"2017","unstructured":"Fust K, Maschio M, Pastor L, et al. A budget impact model of the addition of telotristat ethyl treatment in patients with uncontrolled carcinoid syndrome [abstract no. PSY25 plus poster]. Value Health. 2017;20(9):A548\u20139.","journal-title":"Value Health"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0935-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0935-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0935-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T10:53:46Z","timestamp":1604400826000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0935-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["935"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0935-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"12 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Katherine A. Lyseng-Williamson is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}